Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Bone Therapeutics
Biotech
The 2022 Biotech Graveyard
Biotech's tumbling market has proven especially perilous, and, for many companies, clinical disappointments were followed by financial dead ends and closures.
Max Bayer
Nov 21, 2022 3:00am
Orthopedics biotech finds a Bone in Medsenic reverse merger
Aug 10, 2022 9:16am
Bone breaks from original cell therapy plan, switching endpoint
Jul 15, 2022 8:25am
John Mascola moves on from NIAID's R&D hub—Chutes and Ladders
Apr 1, 2022 9:30am
Layoff surge hits 3 more biotechs
Mar 31, 2022 6:48pm
Cuts to the Bone: Orthopedic biotech slashes C-suite
Mar 29, 2022 11:27am
